A Very Meh-Ry Biotech Year and What’s Ahead in 2025

Episode Summary

Executive Summary: Adam Feuerstein and Daniel Levine review biotech’s uneven 2024: weak M&A, cautious capital markets, persistent layoffs, and a muted IPO backdrop, even as obesity drugs, select approvals, and China-sourced licensing deals kept dealmaking alive. They also assess Trump-era FDA/NIH uncertainty, note a few standout CEO calls, and preview 2025’s JPM, where news flow and M&A will determine sector sentiment.

Main Topics: 2024 biotech performance was sideways, not disastrous (Priority: 5/5): Feuerstein argues the sector underwhelmed versus pre-year expectations: optimism entering 2024 faded as macro uncertainty, election risk, and high interest rates weighed on financing and sentiment. M&A disappointed despite patent-cliff pressure (Priority: 5/5): Deal activity was weaker than expected; a few mid-size acquisitions occurred, but large-scale biotech M&A largely failed to materialize, partly due to stock run-ups, valuation gaps, and possible FTC concerns. Layoffs and capital preservation remained central (Priority: 4/5): Biotech layoffs persisted across startups, commercial biotechs, and even large pharma, reflecting a prolonged cash-conservation mindset and a difficult funding environment. IPO market improved modestly but stayed difficult (Priority: 4/5): Public offerings returned in a limited way, but Feuerstein views the IPO window as still narrow, with reverse mergers emerging as an alternative route to public markets. Drug innovation highlights were selective, not broad-based (Priority: 4/5): The year’s most meaningful approval was Cobenfy for schizophrenia, while the ALS drug withdrawal from Amylyx stood out as a notable failure and a lesson in evidence standards. 2025 policy uncertainty: Trump, RFK Jr., FDA, NIH (Priority: 4/5): The discussion focuses on likely leadership changes and their implications for regulation, vaccines, staffing, and agency culture, with the industry appearing cautiously non-confrontational so far. Obesity, China, and next-wave technologies are shaping 2025 (Priority: 5/5): Obesity remains the dominant biotech theme, while China has become an important source of innovation/licensing. Feuerstein also highlights in vivo editing, ADCs, bispecifics, and protein-degradation-related technologies as areas to watch.

Key Arguments: 2024 was a 'sideways' year because early optimism about M&A did not translate into actual deal volume. High interest rates and the need to preserve cash forced many companies to cut staff or delay expansion. Large pharma may have avoided big acquisitions because of FTC scrutiny and because takeover targets became too expensive after speculation bid up their stocks. The IPO market showed some life, but reverse mergers were often easier than traditional offerings. China has become a genuine source of biotech innovation, not merely a market-access play, and big pharma is licensing more assets there. The most important 2024 drug approval was Cobenfy because it was the first new schizophrenia treatment in two decades. Amylyx’s voluntary withdrawal of its ALS drug was a responsible act after a clearly negative phase 3 readout. There was no single standout 'best CEO' in 2024 because the year produced several good but not singularly dominant management stories. Cassava’s Remy Barbier was the clearest 'worst CEO' choice due to data controversy, regulatory scrutiny, and clinical failure. Obesity drugs continue to dominate biotech economics, attracting capital, generalist investors, and new company formation. M&A/news flow around JPM will be the best indicator of whether biotech sentiment improves in 2025.

Data Points: Year-over-year biotech market character: 'sideways' - Feuerstein’s description of 2024 overall sector performance Large acquisition noted: $16.5 billion - Novo Holdings’ acquisition of Catalent, cited as the main deal above the $1B-$5B range IPO proceeds in first three quarters of 2024: about $3 billion - Biotech IPO fundraising rebounded modestly Biotech IPO count in first three quarters of 2024: 16 deals - Total number of biotech IPOs cited for the period XBI performance: basically flat for the year - Benchmarked against broader market underperformance XBI composition change: shifted toward larger-cap stocks - Made the index less representative of small/mid-cap biotech License deal upfront payments: 5% of total deal value - Down in 2024, per Dealforma and J.P. Morgan quarterly report License deal upfront payments in 2019: 13% of total deal value - Comparison point showing the decline in upfront-heavy deals Lilly market-cap gain context: $1 trillion aggregate market-cap gain over three years - Bruce Booth’s observation about Lilly and Novo obesity-drug value creation Biotech value-creation comparison: 700 IPOs since 2000 + 300 M&A deals created just under $1 trillion - Booth’s benchmark versus GLP-1 value creation Lilly near-trillion valuation: approached $1 trillion market value - Illustrates the scale of obesity-drug enthusiasm Keytruda annual sales benchmark: $25 billion/year - Used to show Zepbound/obesity class will surpass major oncology franchises Editas layoffs: 65% of staff - Example of persistent biotech layoffs in December Amylyx ALS drug failure timing: March/April 2024 - Feuerstein notes the voluntary withdrawal occurred earlier in the year JPM event timing: January 13, 2025, 6–9 p.m. - Stat’s biotech-week event in San Francisco

Pivotal Quotes: "I think it was a very sideways year is the way I think about it now." — Adam Feuerstein: Overall assessment of biotech in 2024 "It was a very down year for M&A in many ways." — Adam Feuerstein: Explaining why pre-year optimism did not translate into expected dealmaking "This was just not, this was not a drug that was going to help anybody with Alzheimer's." — Adam Feuerstein: His criticism of Cassava Sciences’ Alzheimer’s program and rationale for naming its CEO the worst of 2024

Implications: Biotech enters 2025 with selective strength but weak breadth. Obesity, China licensing, and certain platform technologies may drive wins, while funding pressure, policy uncertainty, and the need for real M&A/news flow will shape sentiment at JPM and beyond.